Adjuvants for COVID-19 Vaccines

Area of Science:

• Vaccinology
• Immunology
• Public Health

Background:

• Traditional vaccines evolved from whole virus to protein subunit types, balancing immunogenicity and adverse effects.
• Protein subunit vaccines offer better tolerability but reduced immunogenicity, posing challenges for high-risk populations.
• Adjuvants are crucial for enhancing the immunogenicity of subunit vaccines, improving safety and efficacy.

Purpose of the Study:

• To review the advantages and disadvantages of adjuvants in vaccine development.
• To analyze the role of adjuvanted vaccines in the context of COVID-19.
• To assess the potential of adjuvanted vaccines for future global vaccination strategies.

Main Methods:

• Literature review of vaccine development and adjuvant technology.
• Analysis of clinical data on protein subunit and adjuvanted vaccines.
• Evaluation of immune responses (humoral and cellular) induced by different vaccine types.

Main Results:

• Adjuvants significantly boost the immunogenicity of protein subunit vaccines.
• Adjuvanted vaccines demonstrate improved humoral and cellular immune responses, particularly in elderly populations.
• Recent approvals of protein-based COVID-19 vaccines highlight the growing importance of this platform.

Conclusions:

• Adjuvanted protein subunit vaccines offer a promising strategy to enhance COVID-19 vaccine efficacy and tolerability.
• These vaccines are vital for improving global vaccination coverage, especially for immunocompromised individuals.
• Adjuvants represent a key technology for the future of vaccine development, complementing existing platforms.